Search Results - "Brufsky, A. M."

Long-term survivor characteristics in HER2-positive metastatic breast cancer from registHER by Yardley, D A, Tripathy, D, Brufsky, A M, Rugo, H S, Kaufman, P A, Mayer, M, Magidson, J, Yoo, B, Quah, C, Ulcickas Yood, M

“…Background: Data characterising long-term survivors (LTS) with human epidermal growth factor receptor 2 (HER2)–positive metastatic breast cancer (MBC) are…”
Get full text

Direct interaction between NHERF1 and Frizzled regulates β-catenin signaling by Wheeler, D S, Barrick, S R, Grubisha, M J, Brufsky, A M, Friedman, P A, Romero, G

“…Although Wnt-Frizzled (Fzd) signaling is critical in the pathophysiology of carcinomas, its role in human breast cancer has been difficult to establish. We…”
Get full text

Features associated with long-term survival in metastatic breast cancer by Klar, N., Rosenzweig, M., Diergaarde, B., Brufsky, A.M.

Get full text

Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials by Coleman, R, Powles, T, Paterson, A, Gnant, M, Anderson, S, Diel, I, Gralow, J, von Minckwitz, G, Moebus, V, Bergh, J, Pritchard, KI, Bliss, J, Cameron, D, Evans, V, Pan, H, Peto, R, Bradley, R, Gray, R, Bartsch, R, Dubsky, P, Fesl, C, Fohler, H, Greil, R, Jakesz, R, Lang, A, Luschin-Ebengreuth, G, Marth, C, Mlineritsch, B, Samonigg, H, Singer, CF, Steger, GG, Stoger, H, Olivotto, I, Ragaz, J, Christiansen, P, Ejlertsen, B, Ewertz, M, Jensen, MB, Moller, S, Mouridsen, HT, Eiermann, W, Hilfrich, J, Jonat, W, Kaufmann, M, Kreienberg, R, Schumacher, M, Blohmer, JU, Costa, SD, Eidtmann, H, Gerber, B, Jackisch, C, Loibl, S, Dafni, U, Markopoulos, C, Blomqvist, C, Saarto, T, Ahn, JH, Jung, KH, Perrone, F, Bass, G, Brown, A, Bryant, J, Costantino, J, Dignam, J, Fisher, B, Geyer, C, Mamounas, EP, Paik, S, Redmond, C, Swain, S, Wickerham, L, Wolmark, N, Perez, E, Ingle, JN, Suman, VJ, Hadji, P, A'Hern, R, Dowsett, M, Makris, A, Parton, M, Pennert, K, Powles, TJ, Smith, IE, Yarnold, JR, Clack, G, Van Poznak, C, Safra, T, Bell, R, Coleman, RE, Dodwell, D, Hinsley, S, Marshall, HC, Solomayer, E, Fehm, T, Lester, J, Winter, MC, Horsman, JM, Aft, R, Brufsky, AM, Llombart, HA

“…Summary Background Bisphosphonates have profound effects on bone physiology, and could modify the process of metastasis. We undertook collaborative…”
Get full text

Retrospective study to estimate the prevalence and describe the clinicopathological characteristics, treatments received, and outcomes of HER2-low breast cancer by Viale, G., Basik, M., Niikura, N., Tokunaga, E., Brucker, S., Penault-Llorca, F., Hayashi, N., Sohn, J., Teixeira de Sousa, R., Brufsky, A.M., O’Brien, C.S., Schmitt, F., Higgins, G., Varghese, D., James, G.D., Moh, A., Livingston, A., de Giorgio-Miller, V.

“…Approximately 80% of all breast cancers (BCs) are currently categorized as human epidermal growth factor receptor 2 (HER2)-negative [immunohistochemistry (IHC)…”
Get full text

Comprehensive transcript analysis in small quantities of mRNA by SAGE-Lite by Peters, David G., O'Hare, Elisa Heidrich, Ferrell, Robert E., Kassam, Amin B., Yonas, Howard, Brufsky, Adam M.

“…Serial analysis of gene expression (SAGE) is a powerful technique that can be used for global analysis of gene expression. Its chief advantage over other…”
Get full text

Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer by Sparano, Joseph A, Gray, Robert J, Makower, Della F, Pritchard, Kathleen I, Albain, Kathy S, Hayes, Daniel F, Geyer, Charles E, Dees, Elizabeth C, Goetz, Matthew P, Olson, John A, Lively, Tracy, Badve, Sunil S, Saphner, Thomas J, Wagner, Lynne I, Whelan, Timothy J, Ellis, Matthew J, Paik, Soonmyung, Wood, William C, Ravdin, Peter M, Keane, Maccon M, Gomez Moreno, Henry L, Reddy, Pavan S, Goggins, Timothy F, Mayer, Ingrid A, Brufsky, Adam M, Toppmeyer, Deborah L, Kaklamani, Virginia G, Berenberg, Jeffrey L, Abrams, Jeffrey, Sledge, George W

“…When a genetic test was used to assess prognosis, women with midrange scores were found to have similar outcomes after adjuvant treatment with either endocrine…”
Get full text

Overall survival in the OlympiA phase Ill trial of adjuvant olaparib in patients with germime pathogenic variants in BRCA1/2 and high-risk, early breast cancer by Geyer, C. E., Garber, J. E., Gelber, R. D., Yothers, G., Taboada, M., Ross, L., Rastogi, P., Cui, K., Arahmani, A., Aktan, G., Armstrong, A. C., Arnedos, M., Balmana, J., Bergh, J., Bliss, J., Delaloge, S., Domchek, S. M., Eisen, A., Elsafy, F., Fein, L. E., Fielding, A., Ford, J. M., Friedman, S., Gelmon, K. A., Gianni, L., Gnant, M., Hollingsworth, S. J., Im, S. A., Jager, A., Lakhani, S. R., Janni, W., Linderholm, Barbro, Liu, T. W., Loman, N., Korde, L., Loibl, S., Lucas, P. C., Marme, F., de Duenas, E. M., McConnell, R., Phillips, K. A., Piccart, M., Rossi, G., Schmutzler, R., Senkus, E., Shao, Z., Sharma, P., Singer, C. F., Spanic, T., Stickeler, E., Toi, M., Traina, T. A., Viale, G., Zoppoli, G., Park, Y. H., Yerushalmi, R., Yang, H., Pang, D., Jung, K. H., Mailliez, A., Fan, Z., Tennevet, I., Zhang, J., Nagy, T., Sonke, G. S., Sun, Q., Parton, M., Colleoni, M. A., Schmidt, M., Brufsky, A. M., Razaq, W., Kaufman, B., Cameron, D., Campbell, C., Tutt, A. N. J., Johannsson, O. T.

“…Background: The randomized, double-blind OlympiA trial compared 1 year of the oral poly(adenosine diphosphate-ribose) polymerase inhibitor, olaparib, to…”
Get full text

352PFeatures associated with long-term survival in metastatic breast cancer by Klar, N, Rosenzweig, M, Diergaarde, B, Brufsky, A M

Get full text

The cellular biology of the Reed-Sternberg cell by HALUSKA, F. G, BRUFSKY, A. M, CANELLOS, G. P

Get full text

VP1-2022: Pre-specified event driven analysis of Overall Survival (OS) in the OlympiA phase III trial of adjuvant olaparib (OL) in germline BRCA1/2 mutation (gBRCAm) associated breast cancer by Tutt, A.N.J., Garber, J., Gelber, R.D., Phillips, K-A., Eisen, A., Johannsson, O.T., Rastogi, P., Cui, K.Y., Im, S-A., Yerushalmi, R., Brufsky, A.M., Taboada, M., Rossi, G., Yothers, G., Singer, C., Fein, L.E., Loman, N., Cameron, D., Campbell, C., Geyer, C.E.

Get full text

Recurrent hyperactive ESR1 fusion proteins in endocrine therapy-resistant breast cancer by Hartmaier, R.J., Trabucco, S.E., Priedigkeit, N., Chung, J.H., Parachoniak, C.A., Vanden Borre, P., Morley, S., Rosenzweig, M., Gay, L.M., Goldberg, M.E., Suh, J., Ali, S.M., Ross, J., Leyland-Jones, B., Young, B., Williams, C., Park, B., Tsai, M., Haley, B., Peguero, J., Callahan, R.D., Sachelarie, I., Cho, J., Atkinson, J.M., Bahreini, A., Nagle, A.M., Puhalla, S.L., Watters, R.J., Erdogan-Yildirim, Z., Cao, L., Oesterreich, S., Mathew, A., Lucas, P.C., Davidson, N.E., Brufsky, A.M., Frampton, G.M., Stephens, P.J., Chmielecki, J., Lee, A.V.

“…Estrogen receptor-positive (ER-positive) metastatic breast cancer is often intractable due to endocrine therapy resistance. Although ESR1 promoter switching…”
Get full text

350PPhase Ib study of heat shock protein 90 inhibitor, onalespib in combination with paclitaxel in patients with advanced, triple negative breast cancer (NCT02474173) by Wesolowski, R, Brufsky, A M, Chambers, M, Bhattacharya, S, Lustberg, M, VanDeusen, J B, Sardesai, S, Williams, N, Noonan, A M, Phelps, M, Grever, M, Stephens, J, Carson, W, Ramaswamy, B

“…Abstract Background Heat shock protein 90 (HSP90) is a molecular chaperone required for proper folding and stabilization of proteins. Client proteins of HSP90…”
Get full text

Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer by Ross, L., Eisen, A., Elsafy, F., Fielding, A., Friedman, S., Gianni, L., Phillips, K.-A., Singer, C.F., Toi, M., Park, Y.H., Yang, H., Mailliez, A., Nagy, T., Sonke, G.S., Sun, Q., Colleoni, M.A., Kaufman, B., Cameron, D., Campbell, C., Sevelda, Paul, Öhler, Leopold, Rumpold, Holger, Rautenberg, Beate, Boadle, David, Mackey, John, Niraula, Saroj, Randal d’Hondt, Papadimitriou, Konstantinos, Lazzaro, Mauricio Fernández, Pilnik, Norma, Varela, Mirta, Darsow, Maren, Park-Simon, Tjoung-Won, Terhaag, Jürgen, Salat, Christoph, Dieterich, Max, García Sáenz, José Ángel, Lanza, Angels Arcusa, Quiroga, Vanesa, Jañez, Noelia Martínez, Crusades, Gema Llort, Rodríguez, César, Cretella, Elisabetta, Jegannathen, Apurna, Ishida, Kazushige, Watanabe, Junichiro, Takada, Masahiro, Nakamura, Seigo, Aogi, Kenjiro, Tsugawa, Koichiro, Seaward, Samantha A., Carney, Jennifer Fu, Bobolis, Kristie A., Eisenberg, Peter D., Hofstatter, Erin W., McCarron, Edward C., Herbolsheimer, Pia, Meisel, Jane L., Jones, Cheryl F., Spector, David M., Lo, Shelly S., Cristofanilli, Massimo, Hahn, Olwen M., Oliff, Ira A., Ansari, Bilal, Sharma, Priyanka, Armstrong, Deborah K., VanderWoude, Amy, Friday, Bret E.B., T, Benjamin, Kuzma, Charles S., Radford, James E., Soori, Gamini S., Vogel, Victor G., Wilkinson, Mary, Qamar, Rubina, Loman, Niklas, Silander, Gustav, Abreu, Miguel, Ciruelos Gil, Eva María, Bermejo de las Heras, Begoña, Busch, Steffi, Thomalla, Jörg, Altena, Renske, Chen, Shou-Tung, Huang, Chiun-Sheng, Yeh, Dah-Cherng, Pottier, Virginie, Yang, Hongjian, Fu, Peifen, Wang, Yongsheng, Fan, Zhimin, Landherr, László, Yerushalmi, Rinat, Conte, Pierfranco, Ciccarese, Mariangela, Mackiewicz, Jacek, Kalinka, Ewa, Im, Seock-Ah, Lee, Kyoung Eun

“…The randomized, double-blind OlympiA trial compared 1 year of the oral poly(adenosine diphosphate-ribose) polymerase inhibitor, olaparib, to matching placebo…”
Get full text

Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials by Asselain, Bernard, Barlow, William, Bergh, Jonas, Bergsten-Nordström, Elizabeth, Bliss, Judith, Boccardo, Francesco, Boddington, Clare, Bogaerts, Jan, Bradley, Rosie, Brain, Etienne, Braybrooke, Jeremy, Broet, Philippe, Bryant, John, Burrett, Julie, Cameron, David, Clarke, Mike, Coates, Alan, Coleman, Robert, Coombes, Raoul Charles, Correa, Candace, Costantino, Joe, Cuzick, Jack, Davidson, Nancy, Davies, Christina, Davies, Lucy, Di Leo, Angelo, Dodwell, David, Dowsett, Mitch, Evans, Vaughan, Ewertz, Marianne, Fisher, Bernard, Forbes, John, Ford, Leslie, Gazet, Jean-Claude, Gelber, Richard, Gettins, Lucy, Gianni, Luca, Gnant, Michael, Godwin, Jon, Goldhirsch, Aron, Goodwin, Pamela, Gray, Richard, Hill, Catherine, Ingle, James, Jagsi, Reshma, Jakesz, Raimund, James, Sam, Janni, Wolfgang, Liu, Hui, Liu, Zulian, Lohrisch, Caroline, Loibl, Sibylle, Mamounas, Eleftherios, Mannu, Gurdeep, Martín, Miguel, Mathoulin, Simone, Mauriac, Louis, McGale, Paul, Morris, Philip, Mukai, Hirofumi, Norton, Larry, Ohashi, Yasuo, Olivotto, Ivo, Paik, Soon, Peto, Richard, Piccart, Martine, Pierce, Lori, Poortmans, Philip, Powles, Trevor, Pritchard, Kathy, Ragaz, Joseph, Raina, Vinod, Ravdin, Peter, Read, Simon, Regan, Meredith, Robertson, John, Rutgers, Emiel, Scholl, Suzy, Slamon, Dennis, Sölkner, Lidija, Steinberg, Seth, Sutcliffe, Rosemary, Swain, Sandra, Taylor, Carolyn, Tutt, Andrew, Valagussa, Pinuccia, van de Velde, Cornelis, van der Hage, Jos, Viale, Giuseppe, von Minckwitz, Gunter, Wang, Yaochen, Wang, Zhe, Wang, Xiang, Whelan, Tim, Wilcken, Nicholas, Winer, Eric, Wolmark, Norman, Wood, William, Zambetti, Milvia, Zujewski, Jo Anne

“…Neoadjuvant chemotherapy (NACT) for early breast cancer can make breast-conserving surgery more feasible and might be more likely to eradicate micrometastatic…”
Get full text

Breast Cancer Index Identifies Early-Stage Estrogen Receptor-Positive Breast Cancer Patients at Risk for Early- and Late-Distant Recurrence by YI ZHANG, SCHNABEL, Catherine A, SCHROEDER, Brock E, JEREVALL, Piiha-Lotta, JANKOWITZ, Rachel C, FORNANDER, Tommy, STAL, Olle, BRUFSKY, Adam M, SGROI, Dennis, ERLANDER, Mark G

“…Residual risk of relapse remains a substantial concern for patients with hormone receptor-positive breast cancer, with approximately half of all disease…”
Get full text

Direct interaction between NHERF1 and Frizzled regulates [beta]-catenin signaling by Wheeler, D S, Barrick, S R, Grubisha, M J, Brufsky, A M, Friedman, P A, Romero, G

“…Although Wnt-Frizzled (Fzd) signaling is critical in the pathophysiology of carcinomas, its role in human breast cancer has been difficult to establish. We…”
Get full text

Abstract P6-11-08: Risk of CNS relapse following adjuvant trastuzumab therapy – Updated literature-based meta-analysis by Mathew, A, Brufsky, AM

“…Abstract Background: Randomized trials of adjuvant trastuzumab in HER2-positive early breast cancer observed an increased risk for central nervous system (CNS)…”
Get full text

Long-term treatment with intravenous bisphosphonates in metastatic breast cancer (MBC) by Onishi, T., Singh, V., Rosenzweig, M., Sereika, S., Brufsky, A. M.

“…Abstract only 1035 Background: Intravenous bisphosphonates (IV BPs) are safe and effective in reducing skeletal related events in MBC. The effects of IV BPs…”
Get full text

Abstract P2-10-08: A predictive test for neoadjuvant chemotherapy in breast cancer identifies a subset of triple negative patients with resistant disease and the poorest prognosis by Fournier, MV, Chen, J, Obenauer, J, Goodwin, EC, Tannenbaum, SH, Brufsky, AM

“…Abstract Prediction of pathological complete response (pCR) for neoadjuvant treatment is an area of unmet clinical need, especially for triple negative breast…”
Get full text